Alpha-synuclein transgenic mice: Relevance to multiple system atrophy

Movement Disorders

Volumn 20, Issue SUPPL. 12, 2005, Pages

  Fillon, Gwenaelle ^a   Kahle, Philipp J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Glial cytoplasmic inclusion; Multiple system atrophy; Oligodendrocyte; Synuclein; Transgenic mouse

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; ALPHA SYNUCLEIN; MUTANT PROTEIN; PROTEASOME; PROTEIN KINASE; SERINE; TAU PROTEIN; UBIQUITIN;

ADRENERGIC TRANSMISSION; ARTICLE; CELL INCLUSION; COMORBIDITY; CYTOPATHOLOGY; DISEASE MODEL; MOLECULAR MECHANICS; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; OLIVOPONTOCEREBELLAR ATROPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SHY DRAGER SYNDROME; SOLUBILITY; STRIATONIGRAL DEGENERATION; TRANSGENIC MOUSE; UBIQUITINATION;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; IN SITU HYBRIDIZATION; MICE; MICE, TRANSGENIC; MULTIPLE SYSTEM ATROPHY; OLIGODENDROGLIA; PHOSPHORYLATION; POINT MUTATION; TAU PROTEINS;

EID: 26444544352     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20542     Document Type: Article

References (39)

1. George JM. The synucleins. Genome Biol 2002;3:REVIEWS3002.
2. Li J-Y, Jensen PH, Dahlström A. Differential localization of α-, β- and γ-synucleins in the rat CNS. Neuroscience 2002;113:463-478.
3. Giasson BI, Murray IVJ, Trojanowski JQ, Lee VM-Y. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J Biol Chem 2001; 276:2380-2386.
4. Kahle PJ, Neumann M, Ozmen L, et al. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001;159:2215-2225.
5. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. β-Synuclein inhibits α-synuclein aggregation. A possible role as an anti-parkinsonian factor. Neuron 2001;32:213-223.
6. Uversky VN, Li J, Souillac P, et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synucleins. J Biol Chem 2002; 277:11970-11978.
7. Park JY, Lansbury PT Jr. β-synuclein inhibits formation of α-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003;42:3696-3700.
8. Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:11282-11286.
9. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
10. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18: 106-108.
11. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;388: 839-840.
12. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
13. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathol Appl Neurobiol 2001;27:362-372.
14. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 2000;99:14-20.
15. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79-100.
16. Arima K, Uéda K, Sunohara N, et al. NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol 1998;96:439-444.
17. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-208.
18. Wakabayashi K, Hayashi S, Kakita A, et al. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (Berl) 1998;96:445-452.
19. Tu P, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann Neurol 1998;44:415-422.
20. Dickson DW, Liu W-K, Hardy J, et al. Widespread alterations of α-synuclein in multiple system atrophy. Am J Pathol 1999;155: 1241-1251.
21. Duda JE, Giasson BI, Gur TL, et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of α-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000;59:830-841.
22. Giasson BI, Duda JE, Murray IVJ, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
23. Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-164.
24. Hasegawa M, Fujiwara H, Nonaka T, et al. Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J Biol Chem 2002;277:49071-49076.
25. Kahle PJ, Haass C, Kretzschmar HA, Neumann M. Structure/function of α-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J Neurochem 2002;82:449-457.
26. Rockenstein E, Mallory M, Hashimoto M, et al. Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 2002;68:568-578.
27. van der Putten H, Wiederhold K-H, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WPJM, et al. Neuropathology in mice expressing human α-synuclein. J Neurosci 2000;20:6021-6029.
28. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci 2000;20:6365-6373.
29. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of α-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3:583-588.
30. Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998;57:1099-1111.
31. Neri CL, Duchala CS, Macklin WB. Expression of molecular chaperones and vesicle transport proteins in differentiating oligodendrocytes. J Neurosci Res 1997;50:769-780.
32. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300: 636-640.
33. Jaros E, Burn DJ. The pathogenesis of multiple system atrophy: past, present, and future. Mov Disord 2000;15:784-788.
34. Piao Y-S, Hayashi S, Hasegawa M, et al. Co-localization of α-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathol (Berl) 2001;101:285-293.
35. Takanashi M, Ohta S, Matsuoka S, Mori H, Mizuno Y. Mixed multiple system atrophy and progressive supranuclear palsy: a clinical and pathological report of one case. Acta Neuropathol (Berl) 2002;103:82-87.
36. 1B-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. J Neurochem 2002; 83:623-634.
37. 1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med 2000;6:1388-1394.
38. 1B-adrenergic receptor causes a "seizure plus" syndrome. Nat Med 2001;7:132.
39. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee DH-Y. Mouse model of multiple system atrophy: α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45:847.